BioSenic presents data on its new copper-arsenic trioxide combination for immunological disorders at the 25th International Conference on Redox Medicine

INSIDE INFORMATION

Combining arsenic and a metal ion decreases dosage needed for therapeutic effects in preclinical chronic graft-versus-host disease and systemic sclerosis models

Mont-Saint-Guibert, Belgium, June 20^th 2023, 7.00am CET – BioSenic (Euronext Brussels and Paris: BIOS), the clinical-stage company specializing in serious autoimmune and inflammatory diseases and cell repair, will present the latest data on its arsenic trioxide (ATO) platform at the 25^th International Conference on Redox Medicine 2023, held by Redox Medicine Society on June 21-23 in Paris, France. “Arsenic-Copper: A Double-Edged Sword for a Unique Double Benefit against Immunological Disorders”, will be presented by Dr. Carole Nicco, Chief Scientific Officer at BioSenic and newly elected President of Redox Medicine Society.

The presentation will focus on recent data for ATO, already FDA-approved as an injection to treat acute promyelocytic leukemia. In two recent publications, the company has demonstrated that adding copper improved ATO’s reactive oxygen species (ROS)-mediated deletion of activated immune cells, among other action pathways. This increased efficacy could lead to an improved safety profile, and to new combination therapy approaches with advanced therapy medicinal products (ATMP). BioSenic is already evaluating an oral version of ATO (OATO) for systemic autoimmune indications, including an upcoming Phase III study in patients with chronic graft-versus-host disease following allogeneic hematopoietic stem cell transplant.

“The Redox Medicine Society conference has been running for 25 years, bringing together KOLs and renowned researchers from around the world to facilitate the translation of redox biology into medicine. The Redox Medicine Society congress is a source of fruitful encounters and scientific inspiration.” said Dr. Nicco. “We are excited to share our findings and hope that these data will inspire redox translational research to deliver more beneficial medicines.”

Dr Nicco will present “Arsenic-Copper: A Double-Edged Sword for a Unique Double Benefit against Immunological Disorders” as part of Session 3 on Redox Medicine in Health & Diseases: Innovations, & Strategies, at 9:20 a.m. CEST on Friday, June 23, 2023.

About BioSenic

BioSenic is a leading biotech company specializing in the development of clinical assets issued from: (i), the allogeneic cell therapy platform ALLOB and (ii) the arsenic trioxide (ATO) platform. Key target indications for the platforms include graft-versus-host-disease (GvHD), systemic lupus erythematosus (SLE), systemic sclerosis (SSc) and high-risk tibial fractures.